Bioinformatics Market Size, Share & Trends Analysis Report, By Products & Services (Knowledge Management Tools, Bioinformatics Platforms, Bioinformatics Services), By Purchase Mode (Group Purchase, Individual Purchase), By Sector, By Application, By End User, By Region, And Segment Forecast, 2026-2033

The CAGR is projected to be 13.24% between 2025 and 2032 for the global bioinformatics market. Growth will be driven by advances in personalized medicine, genomics and proteomics research, and increased support for genomic research efforts.

The bioinformatics market's largest segment is Knowledge Management Tools which was valued at USD 8.9 billion in 2024. Knowledge Management Tools consist of various systems and applications that organize, integrate, and interpret biological data, all of which are crucial in the research and pharmaceutical workforce.

Genomics has the largest application in bioinformatics, accounting for about 30% of the market share in 2024. This is due to the influx of next-generation sequencing data and the importance of genomics to personalized medicine and diagnostics, as well as large-scale genome projects.

AI is improving bioinformatics tools and platforms by improving the understanding of complex biological information, increasing the speed and accuracy of predictive modeling, variants analysis, and drug discovery. Tools like ExpasyGPT, allow researchers to create natural language queries across databases.

Cloud-based bioinformatics platforms are making the way in bioinformatics, increasing speed, scalability and cost-effectiveness for what can become incredibly large biological datasets. They allow for real time collaboration, data integration, and access to data, reducing the barrier to entry for many advanced bioinformatics tools.

North America is the leader in bioinformatics with a projected 43% market share in 2024. The U.S has one of the highest healthcare expenditures when compared to other countries and has extensive government support. The above factors have led to North America having some of the world's best biotechnology firms as well as having a heavy concentration of genomic research. The U.S. alone is expected to account for over 85% of the North American market.

Asia-Pacific is the fastest growing region, supported by increased investments in genomics, the adoption of precision medicine, and government support. Countries such as China and India have rapidly increased research and encouraged innovation, thus quickly expanding their bioinformatics ecosystems.

Europe is advancing bioinformatics innovation by building on a rich tradition of fundamental and translational research in genomics and molecular biology, continuous EU and national funding for genomic research, and the institutional and institutional collaboration between academic institutions, biotech companies, and publically funded institutions. The UK is at the forefront in Europe, with initiatives such as Genomics England supporting genomic data analysis.

Genomics is the popular bioinformatic application because it has widespread use in personalized medicine, diagnostics, and population genomics. Moreover, recent advances in next-gen sequencing technologies, combined with low-cost investments to develop genomes and analyze them more rapidly has made genomic data analysis the focus of the future of bioinformatics and its research applications.

Bioinformatics is being used to provide personalized medicine through the utilization of genomic and proteomic data to provide treatments that match individual genetic profiles. Bioinformatics data analysis helps investigators provide better diagnostic specificity and a more individualized treatment option, particularly in oncology and precision diagnostics.

Global Bioinformatics Market size was valued at USD 19.51 Billion in 2024 and is poised to grow from USD 22.09 Billion in 2025 to USD 59.55 Billion by 2033, growing at a CAGR of 13.2% in the forecast period (2026–2033).

The bioinformatics market observes intense competition and innovation. Leading players, such as are Eurofins Scientific, Thermo Fisher Scientific, Inc., and Illumina, Inc., have been adopting strategies centred around integration of technological advances and strategic collaborations. Companies like Qiagen, Agilent Technologies, My Intelligent Machines (MIMs), and LatchBio are using their innovative tools such as QIAGEN’s Microbiome WGS SeqSets and Agilent’s oncology-focused partnership with Theragen Bio. This helps them to improve the precision and efficiency. Many firms are also entering strategic R&D partnerships. Few such instances were seen in Illumina’s alliance with AstraZeneca and Thermo Fisher’s startup incubator collaboration in 2022. These efforts were made to expand the companies’ research capabilities; make bioinformatics tools democratized and gain competitive advantage in the market. Startups are also entering the market to take advantage of its growth. 'Thermo Fisher Scientific, Inc. (United States)', 'Eurofins Scientific SE (Luxembourg)', 'Illumina, Inc. (United States)', 'Revvity Inc (United States)', 'Qiagen N.V. (Netherlands)', 'Agilent Technologies, Inc. (United States)', 'DNASTAR, Inc. (United States)', 'Waters Corporation (United States)', 'Azenta, Inc. (United States)', 'MedGenome Labs Ltd. (India)', 'Fios Genomics (United Kingdom)', 'Genscript Biotech Corporation (China)', 'Dotmatics (United States)', 'Dnanexus, Inc. (United States)', 'Synbio Technologies (United States)', 'NeoGenomics Laboratories (United States)', 'Limerston Capital (Source BioScience) (United Kingdom)', 'Psomagen, Inc. (formerly Macrogen Corp.) (United States / South Korea)', 'LabVantage Solutions, Inc. (Biomax Informatics AG) (United States)', 'Sophia Genetics (Switzerland)'

The increase in regulatory approvals of novel drugs from regulatory bodies such as FDA and Center for Drug Evaluation and Research fuels the demand for bioinformatics solutions. In 2023 alone, the CDER approved 55 novel drugs. This is the second-highest number of approvals in a single year. This increase in approvals shows that the market is progressive towards drug development. This, in turn, indicates the presence of a suitable environment for innovation and market entry. The increased number of FDA approvals directly correlates with heightened research and development (R&D) activities. This creates a direct demand for advanced databases and software tools. Thus, the role of bioinformatics in this transformative journey is more evident now than ever before.

There has been a shift of consumer preference towards subscription-based and pay-per-use models. Companies like Qiagen and Genentech are providing their users access to software and analysis tools through different flexible and affordable subscription plans. This is departing from the traditional upfront licensing fees. This model promotes accessibility and provides cost-effective and adaptable solutions.

As per the 2024 bioinformatics market regional forecast, the North American market is predicted to hold the largest share among all regions in 2024. The region holds 43% of the total market share in 2024. The high spending the region observes on healthcare along with factors such as presence of leading biotech and pharmaceutical companies in the region and strong government funding all contribute to its growth. The high concentration of genomic research initiatives also continues to spur adoption in the region. The US emerges as the hub for bioinformatics in the region.